PARTIAL RESPONSE IN AN RRX-001-PRIMED PATIENT WITH REFRACTORY SMALL-CELL LUNG CANCER AFTER A THIRD INTRODUCTION OF PLATINUM DOUBLETS

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets

Small-cell lung PAL and Coaxial cancer (SCLC), initially exquisitely sensitive to first-line cisplatin/etoposide, invariably relapses and acquires a multidrug chemoresistant phenotype that generally renders retreatment with first-line therapy both futile and counterproductive.This report presents the case of a 77-year-old Caucasian male with extens

read more